actions'' box, enter the docket number ''RHS–24–CF–0027,'' and click the ''Search'' button. From the search results: click on or locate the document title: ''60-Day Notice of Proposed Information Collection: ''Rural Community Development Initiative (RCDI) Grant Program'' and select the ''Comment'' button. Before inputting comments, commenters may review the ''Commenter's Checklist'' (optional). To submit a comment: Insert comments under the ''Comment'' title, click ''Browse'' to attach files (if available), input email address, select box to opt to receive email confirmation of submission and tracking (optional), select the box ''I'm not a robot,'' and then select ''Submit Comment.''

Information on using *Regulations.gov*, including instructions for accessing documents, submitting comments, and viewing the docket after the close of the comment period, is available through the site's ''FAQ'' link.

All comments will be available for public inspection online at the Federal eRulemaking Portal (*regulations.gov*).

FOR FURTHER INFORMATION CONTACT: MaryPat Daskal, Rural Development Innovation Center—Regulations Management Division, USDA, 1400 Independence Avenue SW, Room 4227, South Building, Washington, DC 20250–1522. Telephone: (202) 720–7853. Email: *MaryPat.Daskal@usda.gov*.

SUPPLEMENTARY INFORMATION: The Office of Management and Budget's (OMB) regulation (5 CFR part 1320) implementing provisions of the Paperwork Reduction Act of 1995 (Pub. L. 104–13) requires that interested members of the public and affected agencies have an opportunity to comment on information collection and recordkeeping activities (see 5 CFR 1320.8(d)). This notice identifies the following information collection that RHS is submitting to OMB as a revision to an existing collection with Agency adjustment.

Title: Rural Community Development Initiative (RCDI).

OMB Number: 0575–0180.

Expiration Date of Approval: January 31, 2025.

Type of Request: Revision of a currently approved collection.

Estimate of Burden: This collection of information is estimated to average 1.19 hours per response.

Respondents: Intermediaries and recipients.

Estimated Number of Respondents: 90.

Estimated Number of Responses per Respondent: 38.44.

Estimated Total Number of Responses: 3,460.

Estimated Annual Reporting Burden on Respondents: 3,294 hours.

Estimated Annual Recordkeeping Burden on Respondents: 840 hours.

Estimated Total Annual Burden on Respondents: 4,134 hours.

Abstract

RHS, an Agency within the USDA Rural Development mission area, administers the RCDI grant program through the Community Facilities Division. The intent of the RCDI grant program is to develop the capacity and ability of rural area recipients to undertake projects through a program of technical assistance provided by qualified intermediary organizations. The eligible recipients are nonprofit organizations, low-income rural communities, or federally recognized Indian tribes. The intermediary may be a qualified private, nonprofit, or public (including tribal) organization. The intermediary is the applicant. The intermediary must have been organized a minimum of three (3) years at the time of application. The intermediary will be required to provide matching funds, in the form of cash or committed funding, in an amount at least equal to the RCDI grant.

Information will be collected by the field offices from applicants. The collection of information is considered the minimum necessary to effectively evaluate the overall scope of the project.

Failure to collect information could have an adverse impact on effectively carrying out the mission, administration, processing, and program requirements.

Comments are invited on:

(a) Whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility.

(b) The accuracy of the Agency's estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used.

(c) Ways to enhance the quality, utility, and clarity of the information to be collected; and

(d) Ways to minimize the burden of the collection of information on respondents, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. All responses to this notice will be summarized and included in the request for OMB approval. All comments will become a matter of public record.

Copies of this information collection can be obtained from Lisa Day, Innovation Center—Regulations Management Division, at (971) 313.4750. Email: *Lisa.Day@USDA.GOV*.

All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

Joaquin Altoro,

Administrator, Rural Housing Service.

[FR Doc. 2024–19231 Filed 8–26–24; 8:45 am]

BILLING CODE 3410–XV–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[S–153–2024]

Foreign-Trade Zone 80; Application for Subzone; Senior Operations LLC; New Braunfels, Texas

An application has been submitted to the Foreign-Trade Zones (FTZ) Board by the City of San Antonio, grantee of FTZ 80, requesting subzone status for the facility of Senior Operations LLC, located in New Braunfels, Texas. The application was submitted pursuant to the provisions of the Foreign-Trade Zones Act, as amended (19 U.S.C. 81a–81u), and the regulations of the FTZ Board (15 CFR part 400). It was formally docketed on August 22, 2024.

The proposed subzone (12 acres) is located at 2400 Longhorn Industrial Drive, New Braunfels, Texas. A notification of proposed production activity has been submitted and is being processed under 15 CFR 400.37 (Doc. B–37–2024). The proposed subzone would be subject to the existing activation limit of FTZ 80.

In accordance with the FTZ Board's regulations, Camille Evans of the FTZ Staff is designated examiner to review the application and make recommendations to the Executive Secretary.

Public comment is invited from interested parties. Submissions shall be addressed to the FTZ Board's Executive Secretary and sent to: *ftz@trade.gov*. The closing period for their receipt is October 7, 2024. Rebuttal comments in response to material submitted during the foregoing period may be submitted during the subsequent 15-day period to October 21, 2024.

A copy of the application will be available for public inspection in the ''Online FTZ Information Section'' section of the FTZ Board's website, which is accessible via *www.trade.gov/ftz*.

For further information, contact Camille Evans at *Camille.Evans@trade.gov*.

Dated: August 22, 2024.

Elizabeth Whiteman,

Executive Secretary.

[FR Doc. 2024–19193 Filed 8–26–24; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

AI-Enabled Medical Technologies Industry Roundtable

AGENCY: International Trade Administration, Department of Commerce.

ACTION: Notice.

SUMMARY: The International Trade Administration (ITA) of the Department of Commerce announces a roundtable discussion with industry representatives and U.S. government officials on strategies to increase U.S. industry competitiveness and support commercialization of U.S.-produced artificial intelligence (AI)-enabled medical technologies. ITA invites applications from industry representatives to participate in the roundtables. Applicants should be existing producers/providers or prospective new market entrants in the AI-enabled medical technology sector with solutions that are or will be produced or developed in the United States and exported overseas.

DATES:

Event: The roundtable will be held on Wednesday, October 30, 2024, from 2:30 p.m. to 4:30 p.m., Eastern Daylight Time.

Event Registration: ITA will evaluate registrations based on the submitted information (see below) and inform applicants of selection decisions, which will be made on a rolling basis until a maximum of 20 participants have been selected.

ADDRESSES:

Event: The roundtable will be held via Microsoft Teams, and the link for the meeting will be provided to selected and registered participants.

FOR FURTHER INFORMATION CONTACT: Liam Kraft at 771–216–4432 or via email at *HealthAI@trade.gov.*

SUPPLEMENTARY INFORMATION: AI is anticipated to yield significant growth opportunities for the healthcare sector. With AI regulation and policy formation still nascent in many markets, it is important to understand the implications of changes in these areas for U.S. healthcare industry stakeholders as governments, practitioners, and patients increasingly adopt AI solutions in healthcare and as demand for AI-enabled medical technologies grows in overseas markets. This discussion will help position ITA to work with U.S. industry stakeholders in ways that can enhance U.S. industry competitiveness in overseas markets and reduce current or future trade barriers faced by companies in this space.

The Department seeks individual input and views at the 10/30/2024 roundtable regarding overseas competitiveness of U.S. companies producing, or planning to produce, and exporting AI-enabled medical technologies. Participants will be encouraged to provide any relevant feedback on this issue during the roundtable, which may include comments on the following non-exhaustive list of possible topics:

- With the introduction of technologies such as foundational models and general-purpose AI, what are the implications of regulatory and policy shifts in markets to which your company exports AI-enabled medical technologies, and how have these changes affected your company's competitiveness?
- Which markets, given shifting regulatory and policy landscapes, present the most conducive environment for the competitiveness of U.S. AI-enabled medical technologies, from your experience?
- How do you assess the potential for public-private partnerships (P3s) to support efforts in the healthcare sector to deliver AI-enabled medical technologies to overseas markets? What would a successful P3 in this space look like? What kind of resources are needed from the U.S. Government to enable this success?
- What kinds of strategic international engagements do you believe would be most effective in supporting U.S. providers of AI-enabled medical technologies and their competitiveness in overseas markets?
- What kinds of trade barriers are you seeing negatively affect U.S. competitiveness for AI-enabled medical technologies in overseas markets? Where do you encounter these barriers? How do you think the barriers can be reduced, removed, or prevented?
  - What are the implications of regulations/policies around health data in foreign markets for U.S. competitiveness in AI-enabled medical technologies that you're seeing in your work?

The event is closed to press and the public. Industry participation is limited to a maximum of 20 qualifying industry representatives.

Selection

To attend, participants should submit the below information to *HealthAI@trade.gov* by no later than 10/23/2024. ITA will evaluate registrations based on the submitted information (and based on the criteria below) on a rolling basis until a maximum of 20 participants have been selected and inform applicants of selection decisions.

Applicants are encouraged to send representatives at a sufficiently senior level to be knowledgeable about their company's capabilities, interests, and challenges in the global market of AI-enabled medical technologies. Due to time constraints, there is a limit of one person to speak on behalf of each company.

Applicants should include the following information in their response email:

- Name of attendee and short bio.
- Name of company and brief company description.
- A statement self-certifying how the company meets each of the following criteria:

1. It is not majority owned by a foreign government entity (or entities).

2. It is an existing provider or prospective new market entrant, of AI-enabled medical technologies that are or will be produced in the United States in one or more of the following segments: Machine learning, natural language processing, clinical, disease detection, medical imaging, personalized care, patient monitoring, robotics, or healthcare administration.

3. The representative will be able to attend the entire roundtable.

Selection will be based on the following criteria:

- The company's production or production plans with respect to AI-enabled medical technologies.
- The company's experience in exporting AI-enabled medical technologies from the United States to overseas markets.
- Suitability of the representative's position and biography to be able to engage in the conversation.
- Ability of the company to contribute to the roundtable's purpose of seeking individual input and views on policies and initiatives that strengthen U.S. industry competitiveness of U.S. exports.

Dated: August 20, 2024.

Amanda Lawrence,

Acting Director, Office of Health Industries, International Trade Administration.

[FR Doc. 2024–19040 Filed 8–26–24; 8:45 am]

BILLING CODE 3510–DR–P